Gano Kyle
Chief Executive Officer | Chief Business Development Off
1 company
Insider Signal Score
54
AverageTrades Analyzed
18
12M Win Rate
23.5%
Avg 3M Return
+4.0%
Avg 12M Return
-15.9%
Gano Kyle is a Chief Executive Officer at NEUROCRINE BIOSCIENCES INC. Recent SEC Form 4 filings include 0 buys and 15 sells.
Estimated insider holdings value: $22.7M based on current market prices.
Holdings by Company
NBIXNov 4, 2025
Current Shares140.4K
Value$22.69M
Net Activity-367,574
Bought: 0Sold: 367.6K
Transaction History
Showing 10 filings (page 3)
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2019 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sell | 762 | $83.56 | $63,672.64 | -0.9% | |
| Feb 5, 2019 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sell | 3,809 | $88.12 | $335,667.92 | -1.1% | |
| Aug 1, 2018 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sale+OE | 28,266 | $115.00 | $3,250,590.00 | -26.4% | |
| Mar 5, 2018 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sale+OE | 23,650 | $90.00 | $2,128,500.00 | -23.1% | |
| Feb 5, 2018 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sell | 2,046 | $83.05 | $169,913.91 | -1.3% | |
| Jan 16, 2018 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sell | 1,625 | $79.05 | $128,459.50 | -2.1% | |
| Nov 2, 2017 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sale+OE | 24,818 | $71.05 | $1,763,318.90 | -14.5% | |
| Sep 6, 2017 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sale+OE | 20,393 | $60.00 | $1,223,580.00 | -21.8% | |
| Sep 6, 2017 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sale+OE | 4,607 | $60.00 | $276,420.00 | -5.9% | |
| May 1, 2017 | NBIX Neurocrine Biosciences Inc | Chief Business Development Off | Sale+OE | 15,000 | $54.00 | $810,000.00 | -17.0% |